TABLE 2.
Antifungal susceptibility testing of Aspergillus species isolated from culturesa
| MIC |
IC50 |
IC50 |
MEC |
||||||
|---|---|---|---|---|---|---|---|---|---|
| Case no. | Species | Prophylaxisb | AMB | ITC | VRC | POS | FLC | 5FC | MFG |
| Case 1 | A. turcosus | MFG | 0.5 | 0.25 | 0.5 | 0.25 | 16 | >64 | <0.015 |
| Case 2 | A. felis | MFG | 2 | 8 | 4 | NA | >64 | >64 | 0.03 |
| Case 3 | A. viridinutans | ITC | 4 | 2 | 2 | 1 | >64 | >64 | 0.015 |
| Case 4 | A. nidulans | FLC | 2 | 0.12 | 0.12 | NA | 64 | >64 | <0.015 |
| Case 5 | A. calidoustus | ITC | NA | NA | NA | NA | NA | NA | NA |
| Case 6 | A. fumigatus | VRC | NA | NA | NA | NA | NA | NA | NA |
| Case 7 | A. fumigatus | VRC | 2 | 8 | 2 | NA | >64 | >32 | 0.015 |
| Case 8 | A. fumigatus | L-AMB 3 mg/kg | 0.25 | 0.25 | 1 | NA | >64 | >64 | <0.015 |
a
MIC, MIC; IC50, half-maximal inhibitory concentration; MEC, minimum effective concentration; AMB, amphotericin B; ITC, itraconazole; VRC, voriconazole; POS, posaconazole; FLC, fluconazole; 5FC, 5-fluorocytosine; MFG, micafungin; L-AMB, liposomal amphotericin B; NA, not available.
b
Antifungal agents administered on the day of IA onset.